Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 3, pp 418–421 | Cite as

Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report

  • Seher GokayEmail author
  • Davran Cicek
  • Haldun Muderrisoglu
Case Report

Abstract

Case Although newer cancer treatments and supportive care treatments have led to vast improvements in the management of complications associated with cancer treatment, sometimes they might cause serious side effects such as coronary artery disease, myocardial infarction and heart failure. These complications may occur any time during or after chemotherapeutics. In this report we present a patient with prostate cancer who experienced myocardial infarction and stent thrombosis probably caused by cabazitaxel -a new chemotherapeutic agent- administration. Conclusion Cardiologists and oncologists should take into consideration the cardiac side effects of new chemotherapeutic agents with the aim of maximizing both quality of life and survival.

Keywords

Acute myocardial infarction Cabazitaxel Cancer Cardiotoxicity 

Notes

Acknowledgments

We wish to thank the patient, his family members, and our co-workers for their contribution to this study.

Funding

All supports for this study came from institutional and departmental resources.

Conflicts of interest

The authors of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

References

  1. 1.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506.PubMedCrossRefGoogle Scholar
  3. 3.
    Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21(6):578–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.PubMedCrossRefGoogle Scholar
  5. 5.
    Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008;12(4):627–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Łacko A, Włodarska I, Zymliński R, Mazur G, Wróbel T, Gisterek I. Cardiac toxicity in cancer therapy. Pol Merkur Lekarski. 2002;13(73):79–85.PubMedGoogle Scholar
  7. 7.
    Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Vorinostat (Zolinza). Package insert. Whitehouse Station, NJ: Merck & Co. Inc. 2010.Google Scholar
  9. 9.
    Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.PubMedCrossRefGoogle Scholar
  10. 10.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs. 2011;71(10):1251–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117–24.PubMedGoogle Scholar
  14. 14.
    De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.PubMedCrossRefGoogle Scholar
  15. 15.
    De Bono JS, Sartor O. Cabazitaxel for castration-resistant prostate cancer—author’s reply. Lancet. 2011;377(9760):122–3.CrossRefGoogle Scholar
  16. 16.
    Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, et al. Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123(16):1745–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug events. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Seher Gokay
    • 1
    Email author
  • Davran Cicek
    • 1
  • Haldun Muderrisoglu
    • 2
  1. 1.Department of CardiologyBaşkent University School of MedicineAlanyaTurkey
  2. 2.Department of CardiologyBaşkent University School of MedicineAnkaraTurkey

Personalised recommendations